>Would appreciate comments on the briefing documents suggestion that overall survival appears to be trending toward final significance<
This means the patients in the Satraplatin arm are living longer than the patients in the control arm, but we don’t yet know whether the difference will be statistically significant.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”